UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of October 2019

 

001-36345

(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

16 Tiomkin St.

Tel Aviv 6578317, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x      Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

  

 

  

 

  

Attached hereto and incorporated herein by reference is a press release, dated October 31, 2019, and entitled “Galmed Pharmaceuticals to Present New Data on Aramchol effect on glucose metabolism, MoA and clinical results at AASLD 2019.”

 

The first paragraph and “Forward Looking Statements” of the press release attached to this Form 6-K are incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-223923).

 

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Galmed Pharmaceuticals Ltd.
   
Date:  October 31, 2019 By: /s/ Allen Baharaff
    Allen Baharaff
    President and Chief Executive Officer

 

  

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Galmed Pharmaceuticals Charts.
Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Galmed Pharmaceuticals Charts.